menu search

ACHV / Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug Read More
Posted: Apr 4 2022, 13:38
Author Name: Seeking Alpha
Views: 102727

ACHV News  

Achieve: Exciting Smoking Cessation Drug Approval Could Come Soon

By Seeking Alpha
May 28, 2023

Achieve: Exciting Smoking Cessation Drug Approval Could Come Soon

Efficacy: Phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinforcing data from ORCA-2. Safety: Cytisinicline more_horizontal

Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results

By Market Watch
May 23, 2023

Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results

Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine de more_horizontal

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

By GlobeNewsWire
April 26, 2023

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmace more_horizontal

Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 16, 2023

Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Rel more_horizontal

Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

By Seeking Alpha
January 28, 2023

Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase more_horizontal

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Nicole Jones - Investor more_horizontal

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 12, 2022

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director more_horizontal

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

By Seeking Alpha
April 4, 2022

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug more_horizontal


Search within

Pages Search Results: